Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$3.7 million.

  • Anika Therapeutics' Change in Accured Expenses rose 64.09% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 28.80%. This contributed to the annual value of -$3.7 million for FY2024, which is 322.63% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Change in Accured Expenses is -$3.7 million, which was down 322.63% from $1.6 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Change in Accured Expenses registered a high of $3.5 million during FY2021, and its lowest value of -$3.7 million during FY2024.
  • In the last 3 years, Anika Therapeutics' Change in Accured Expenses had a median value of -$443,000 in 2022 and averaged -$821,333.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 2,571.83% in 2021, then tumbled by 322.63% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Change in Accured Expenses stood at -$142,000 in 2020, then spiked by 2,571.83% to $3.5 million in 2021, then crashed by 112.62% to -$443,000 in 2022, then spiked by 472.01% to $1.6 million in 2023, then crashed by 322.63% to -$3.7 million in 2024.